Diminished 11β-Hydroxysteroid dehydrogenase type 2 activity is associated with decreased weight and weight gain across the first year of life

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages

  Rogers, Samantha L ^a   Hughes, Beverly A ^a   Jones, Christopher A ^a   Freedman, Lauren ^a   Smart, Katherine ^a   Taylor, Norman ^b   Stewart, Paul M ^a   Shackleton, Cedric H L ^a,c   Krone, Nils P ^a   Blissett, Jacqueline ^a   Tomlinson, Jeremy W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; GLUCOCORTICOID; STEROID 5ALPHA REDUCTASE;

ADULT; ARTICLE; CHILD DEVELOPMENT; CHILD GROWTH; CORTICOSTEROID METABOLISM; CORTICOSTEROID RELEASE; ENZYME ACTIVITY; FEMALE; HUMAN; INFANT; LONGITUDINAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; URINARY EXCRETION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; BODY WEIGHT; CHILD DEVELOPMENT; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84899903193     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3254     Document Type: Article

References (56)

1. Rinaudo P, Wang E. Fetal programming and met abolic syndrome. Annu Rev Physiol. 2012;74:107-130.
2. Dimitriou T, Maser-Gluth C, Remer T. Adrenocortical activity in healthy children is associated with fat mass. Am J Clin Nutr. 2003; 77(3):731-736.
3. Stewa rt PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84(3):1022-1027.
4. Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11-hydroxysteroid dehydrogenase type 1 express ion and elevated hepatic 5-reductase activity. Diabetes. 2008;57(10):2652-2660.
5. Verhaeghe J, van Bree R, van Herck E, Coopmans W. Exogenous corticosteroids and in utero oxygenation modul ate indices of fetal insulin secretion. J Clin Endocrinol Metab. 2005;90(6):3449-3453.
6. Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterati ons in aortic function and glucose metabolism. Pediatrics. 2012;129(5):e1282-e1290.
7. Cleasby ME, Kelly PA, Walker BR, Seckl JR. Programming of rat muscle and fat metabolism by in utero overexp osure to glucocorticoids. Endocrinology. 2003;144(3):999-1007.
8. Smith JT, Waddell BJ. Increased fetal glucocorticoid exposure delays puberty onset in postnatal life. Endocrinology. 2000;141(7): 2422-2428.
9. Mune T, Rogerson FM, NikkiläH, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-399.
10. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab. 2001;86(10): 4979-4983.
11. Palermo M Shackleton CH Mantero F Stewart PM. Urinary free cortisone and the assessment of 11-hydroxysteroid dehydrogenase activity in man Clin Endocrinol (Oxf). 1996 45(5): 605-611.
12. Shackleton CH, Honour JW, Taylor NF. Metabolism of fetal and neonatal adrenal steroids. J Steroid Biochem. 1979;11(1B):523-529.
13. Remer T, Maser-Gluth C, Wudy SA. Glucocorticoid measurements in health and disease-metabolic implications and the potential of 24-h urine analyses. Mini Rev Med Chem. 2008;8(2):153-170.
14. Lawson AJ, Walker EA, La very GG, et al. Cortisone-reductase deficiency associated with heterozygous mutations in 11-hydroxysteroid dehydrogenase type Proc Natl Acad Sci USA. 2011; 108(10):4111-4116.
15. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11-hydroxysteroid dehydrogenase (11-HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11-HSD1 inhibitor. J Clin Endocrino l Metab. 2008;93(2):550-556.
16. Condon J, Gosden C, Gardener D, et al. Expression of type 2 11-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab. 1998;83: 4490-4497.
17. Costa A, Rocci MP, Arisio R, et al. Glucocorticoid receptors immunoreactivity in tissue of human embryos. J Endocrinol Invest. 1996;19(2):92-98.
18. Cole TJ, Blendy JA, Monaghan AP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes De v. 1995; 9(13):1608-1621.
19. Kattner E, Metze B, Waiss E, Obladen M. Accelerated lung maturation following maternal steroid treatment in infants born before 30 weeks gestation. J Perinat Me d. 1992;20(6):449-457.
20. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978;202:436-438.
21. Bloom SL, S heffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol. 2001; 97(4):485-490.
22. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and cause s glucose intolerance in adult offspring. J Clin Invest. 1998;101(10):2174-2181.
23. Martinerie L, Pussard E, Meduri G, Delezoide AL, Boileau P, Lombes M. Lack of renal 11-hydroxyst eroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice. PLoS One. 2012;7(2):e31949.
24. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993;34l:339-341.
25. Stewart PM, Rogerson FM, Mason JI. Type 2 11-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 1995;80(3):885-890.
26. Rogerson FM, Kayes MK, White PC. Variation in placental type 2 11-hydroxysteroid dehydrogenase activity is not related to birth or placental weight. Mol Cell Endocrinol. 1997;128:103-109.
27. Lindsay RS, Linds ay RM, Edwards CRW, Seckl JR. Inhibition of 11-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension. 1996; 27(6):1200-1204.
28. Hol mes MC, Abrahamsen CT, French KL, Paterson JM, Mullins JJ, Seckl JR. The mother or the fetus 11-Hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoid s. J Neurosci. 2006; 26(14):3840-3844.
29. Hassan-Smith Z, Stewart PM. Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011;18(3): 177-185.
30. Knops NB, Monnens LA, Lenders JW, Levtchenko EN. Apparent mineralocorticoid excess: time of manifestation and complications despite treatment. Pediatrics. 2011;127(6):e1610-e1614.
31. Weng SF Redsell SA Swift JA Yang M Glazebrook CP. Systematic review and meta-analyses of risk factors for childhood overweight identifiable during infancy Arch Dis Child. 2012;97(12) 1019-1 026.
32. Jinno K, Sakura N, Nomura S, Fujitaka M, Ueda K, Kihara M. Failure of cortisone acetate therapy in 21-hydroxylase deficiency in early infancy. Pediatr Int. 2001;43(5):478-48 2.
33. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monother apy. Diabetes Care. 2010;33(7):1516-1522.
34. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 dia betes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13(6):498-504.
35. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11-hydroxysteroid dehydrogenase type 1 knockout mice show attenu ated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94(26):14924-14929.
36. Thigpen AE, Davis DL, Milatovich, et al. Molecular genetics of steroid 5-reductase 2 deficiency. J Clin Invest. 1992;90(3):799-809.
37. Russell DW, Wilson JD. Stero id 5-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61.
38. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5-red uctase activity and adipose tissue insulin sensitization following weight loss. Diabetes. 2008;57(6):1536-1543.
39. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab. 2003;88(10):4924-4931.
40. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol me-tabolism in polycystic ovary syndrome: insulin enhances 5-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab. 2003;88(12):5907- 5913.
41. Kamrath C, Hartmann MF, Remer T, Wudy SA. The activities of 5-reductase and 17,20-lyase determine the direction through androgen synthesis pathways in patients with 21-hydroxylase deficiency. Steroids. 2012; 77(13):1391-1397.
42. Berry LM, Polk DH, Ikegami M, Jobe AH, Padbury JF, Ervin MG. Preterm newborn lamb renal and cardiovascular responses after fetal or maternal antenatal betamethasone.AmJ Physi ol. 1997;272(6 Pt 2):R1972-R1979.
43. Ortiz LA, Quan A, Weinberg A, Baum M. Effect of prenatal dexamethasone on rat renal development. Kidney Int. 2001;59(5):1663-1669.
44. Bian X, Seidler FJ, Slotkin TA. Fetal dexamethasone exposure interferes with establishment of cardiac noradrenergic innervation and sympathetic activity. Teratology. 1993;47(2):109-117.
45. Hadoke PW, Lindsay RS, Seckl JR, Walker BR, Kenyon CJ. Altered vascular contractility in adult female rats with hypertension programmed by prenatal glucocorticoid exposure. J Endocrinol. 2006; 188(3 ):435-442.
46. Sloboda DM, Newnham JP, Challis JR. Repeated maternal glucocorticoid administration and the developing liver in fetal sheep. J Endocrinol. 2002;175(2):535-543.
47. Drake AJ, Raubenheimer PJ, Kerrigan D, McInnes KJ, Seckl JR, Walker BR. Prenatal dexamethasone programs expression of genes in liver and adipose tissue and increased hepatic lipid accumulation but not obesity on a hi gh-fat diet. Endocrinology. 2010;151(4): 1581-1587.
48. Dumortier O, Theys N, Ahn MT, Remacle C, Reusens B. Impairment of rat fetal-cell development by maternal exposure to dexamethasone d uring different time-windows. PLoS One. 2011;6(10): e25576.
49. Tang JI, Kenyon CJ, Seckl JR, Nyirenda MJ. Prenatal overexposure to glucocorticoids programs renal 11-hydroxysteroid dehydrogenas e type 2 expression and salt-sensitive hypertension in the rat. J Hypertens. 2011;29(2):282-289.
50. Nyirenda MJ, Carter R, Tang JI, et al. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11-hydroxysteroid dehydrogenase type 1. Diabetes. 2009;5 8(12):2873-2879.
51. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001; 294(5549):2166-2170.
52. McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat antenatal glucocorticoids for women at risk of preterm birth: a Cochrane systematic review. Am J Obstet Gynecol. 2012;206(3):187-194.
53. Simoni M Khan SA Nieschlag E. Serum bioactive follicle-stimulating hormone-like activity in human pregnancy is a methodological artifact J Clin Endocrinol Metab.1991 73 1118-1122
54. Doyle LW, Ford GW, Rickards AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 2000;106(1):E2.
55. Dalziel SR, Walk er NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet. 2005;365(9474):1856-1862.
56. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. Arch Dis Child Fetal Neonatal Ed 2008;93(6):F442-F447.